Evidence map›Paper›PMID 34026925›Full record

ArticleOncoscience2021

Constitutive activation of MEK5 promotes a mesenchymal and migratory cell phenotype in triple negative breast cancer.

Margarite D Matossian, Van T Hoang, Hope E Burks, Jacqueline La, Steven Elliott, Courtney Brock, Douglas B Rusch, Aaron Buechlein, Kenneth P Nephew, Akshita Bhatt and 4 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncoscience, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Margarite D MatossianDepartment of Medicine, Division of Hematology and Oncology, Tulane University, New Orleans, LA 70118, USA.
Van T HoangDepartment of Medicine, Division of Hematology and Oncology, Tulane University, New Orleans, LA 70118, USA.
Hope E BurksDepartment of Medicine, Division of Hematology and Oncology, Tulane University, New Orleans, LA 70118, USA.
Jacqueline LaDepartment of Medicine, Division of Hematology and Oncology, Tulane University, New Orleans, LA 70118, USA.
Steven ElliottDepartment of Medicine, Division of Hematology and Oncology, Tulane University, New Orleans, LA 70118, USA.
Courtney BrockDepartment of Medicine, Division of Hematology and Oncology, Tulane University, New Orleans, LA 70118, USA.
Douglas B RuschCenter for Genomics and Bioinformatics, Indiana University, Bloomington, IN 47405, USA.
Aaron BuechleinMedical Sciences Program, Indiana University School of Medicine-Bloomington, Bloomington, IN 47405, USA.
Kenneth P NephewMedical Sciences Program, Indiana University School of Medicine-Bloomington, Bloomington, IN 47405, USA.
Akshita BhattDepartment of Pharmacology, Duquesne University School of Pharmacy, Pittsburgh, PA 15282, USA.
Jane E CavanaughDepartment of Pharmacology, Duquesne University School of Pharmacy, Pittsburgh, PA 15282, USA.
Patrick T FlahertyDepartment of Medicinal Chemistry, Duquesne University School of Pharmacy, Pittsburgh, PA 15282, USA.
Bridgette M Collins-BurowDepartment of Medicine, Division of Hematology and Oncology, Tulane University, New Orleans, LA 70118, USA.
Matthew E BurowDepartment of Medicine, Division of Hematology and Oncology, Tulane University, New Orleans, LA 70118, USA.
Tulane University · USDuquesne University · USIndiana University Bloomington · USIndiana University School of Medicine

Funding

NRSA Training CoreTL1TR003106 · NCATS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI SAAG, KENNETH G · 2019 to 2023
$3.7M
Kinase mediated suppression of metastasis in breast cancerR01CA174785 · NCI · TULANE UNIVERSITY OF LOUISIANA · PI COLLINS-BUROW, BRIDGETTE MICHELLE · 2016 to 2020
$1.8M
MEK5-Erk5 in breast cancer resistanceR01CA125806 · NCI · TULANE UNIVERSITY OF LOUISIANA · PI BUROW, MATTHEW E. · 2010 to 2014
$1.5M
Novel small molecule inhibitors of MEK5_ERK5 for the treatment of breast cancerR15CA176496 · NCI · DUQUESNE UNIVERSITY · PI CAVANAUGH, JANE E · 2014 to 2014
$394k
NCATS NIH HHS TL1 TR003106NCI NIH HHS R01 CA125806NCI NIH HHS R01 CA174785NCI NIH HHS R15 CA176496
6 · The paper itself

Abstract

Triple negative breast cancer (TNBC) is an aggressive subtype of breast cancer with limited targeted therapeutic options. A defining feature of TNBC is the propensity to metastasize and acquire resistance to cytotoxic agents. Mitogen activated protein kinase (MAPK) and extracellular regulated kinase (ERK) signaling pathways have integral roles in cancer development and progression. While MEK5/ERK5 signaling drives mesenchymal and migratory cell phenotypes in breast cancer, the specific mechanisms underlying these actions remain under-characterized. To elucidate the mechanisms through which MEK5 regulates the mesenchymal and migratory phenotype, we generated stably transfected constitutively active MEK5 (MEK5-ca) TNBC cells. Downstream signaling pathways and candidate targets of MEK5-ca cells were based on RNA sequencing and confirmed using qPCR and Western blot analyses. MEK5 activation drove a mesenchymal cell phenotype independent of cell proliferation effects. Transwell migration assays demonstrated MEK5 activation significantly increased breast cancer cell migration. In this study, we provide supporting evidence that MEK5 functions through FRA-1 to regulate the mesenchymal and migratory phenotype in TNBC.

Indexed as

cell migrationepithelial to mesenchymal transitionERK5MEK5triple negative breast cancer

Identifiers

PMID34026925
PMCPMC8131078
OpenAlexW3164472337

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.